Retatrutide

Retatrutide, often nicknamed “Triple G”, is a novel, investigational therapeutic peptide developed by Eli Lilly and Company. It is a first-in-class triple receptor agonist being studied primarily for the treatment of obesity and related metabolic conditions like Type 2 Diabetes Mellitus and Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD/NAFLD).

Key Features & Mechanism of Action

Retatrutide’s unique strength lies in its multi-pronged approach, acting as an agonist on three key human hormone receptors involved in regulating metabolism, satiety, and energy balance:

Glucagon-Like Peptide-1 (GLP-1) Receptor Agonism:

1. • Effect: Slows gastric emptying, enhances the feeling of fullness (satiety), suppresses appetite, and stimulates glucose-dependent insulin secretion.
   • Glucose-Dependent Insulinotropic Polypeptide (GIP) Receptor Agonism:
     • Effect: Further supports glucose-dependent insulin secretion, improves insulin sensitivity, and is involved in fat metabolism.Glucagon Receptor (GCGR) Agonism:
       • Effect: Promotes energy expenditure and the breakdown of fat stores (lipolysis), contributing to a potent metabolic boost that complements the appetite-suppressing effects of the GLP-1 and GIP components.
       • This triple-action mechanism is designed to provide comprehensive metabolic control and may lead to superior clinical outcomes compared to single or dual-receptor agonists currently available.

Potential Therapeutic Indications

Obesity and Overweight: Being investigated as a treatment for significant weight reduction in adults with obesity or overweight and related comorbidities.

Type 2 Diabetes Mellitus: Studied for its potential to improve glycemic control by regulating blood sugar levels.

Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD/NAFLD): Research is ongoing to assess its potential to reduce liver fat accumulation.

Administration & Efficacy

Administration: Expected to be a once-weekly subcutaneous injection.

Clinical Trial Results (Phase 2): In clinical trials for weight loss in adults with obesity, Retatrutide demonstrated significant efficacy, achieving a mean weight reduction of up to 24.2% over 48 weeks at the highest dose (12 mg).

Status

Retatrutide is currently in Phase 3 clinical trials (as of late 2025) and is not yet approved by regulatory bodies like the FDA or EMA for commercial use. It remains an investigational drug.